Biểu đồ giá cổ phiếu CGON
CGON Thu nhập
CG Oncology Inc
$69.53
-6.03%
$-4.46
Khi đóng cửa: May 14, 16:00:00 GMT-4
$69.51
-0.03%
$-0.02
Phiên trước giờ: May 15, 07:40:30 GMT-4
Quay lại
CG Oncology Inc (CGON) Thu nhập
Thống kê chính
Giá đóng cửa trước
$74
Giá mở cửa
$74.77
Phạm vi ngày
$68.07 - $75.5
Phạm vi 52 tuần
$21 - $73.56
Khối lượng
1.1M
Khối lượng trung bình
1.2M
Tỷ suất cổ tức
--
EPS (TTM)
-2.83
Vốn hóa thị trường
$5.8B
CGON là gì?
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 142 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
